Cervical Abnormalities in South African Women Living With HIV With High Screening and Referral Rates

Ingrid T. Katz  
Lisa M. Butler  
Tamaryn L. Crankshaw  
Alexi A. Wright  
Karen Bramhill  
Dominick A. Leone  
Janet Giddy  
Sean Mould

Author affiliations appear at the end of this article. I.T.K. and L.M.B. contributed equally to this work.

Supported by the US National Institutes of Health, National Institute for Mental Health Grant No. K23-MH097667 (I.T.K.) and National Cancer Institute Grant No. K07-CA166210 (A.A.W.).

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors’ disclosures of potential conflicts of interest and contributions are found at the end of this article.

Corresponding author: Ingrid T. Katz, MD, MHS, 1620 Tremont St, 3rd Floor, Brigham and Women’s Hospital, Division of Women’s Health, Boston, MA 02120; e-mail: ikatz2@partners.org.

Purpose To determine the prevalence of screening, cervical dysplasia, and malignancy on the basis of histologic diagnoses from colposcopy and large loop excision of the transformation zone among women living with HIV (WLWH) who attended an urban antiretroviral treatment (ART) clinic in KwaZulu-Natal, South Africa.

Materials and Methods We performed a retrospective cohort study to examine a random sample of 462 WLWH during a 5-year period from 2004 to 2009. Women on ART for < 3 months were excluded. Data were abstracted from electronic records and paper charts to assess rates of cervical abnormalities detected on Papanicolau test as well as time to colposcopy.

Results During the study period, 432 women (93.5%) had at least one evaluable Papanicolau test. At baseline, 237 women (54.9%) had an abnormal Papanicolau test, and of these patients, 181 (76.3%) had a Papanicolau test that qualified for further colposcopic evaluation. In addition, 115 women (63.5%) received colposcopy within a median of 39 days from referral. This yielded 74 evaluable histologic samples (64.3%), of which 21.6%, 27.0%, 27.0%, and 1.4% had cervical intraepithelial neoplasia (CIN) 1, CIN2, CIN3, and invasive cervical cancer, respectively.

Conclusion In a large sample of WLWH who received ART in KwaZulu-Natal, South Africa, where Papanicolau test coverage and rates of referral for colposcopy and large loop excision of the transformation zone were high, > 75% of women with evaluable histologic samples had evidence of cervical dysplasia or malignancy. These findings underscore the importance of routine cervical screening upon entry into HIV care to optimize survival.

INTRODUCTION

Cervical cancer is the fourth most common cancer among women worldwide and accounts for > 500,000 cases diagnosed annually.1 The burden of cervical cancer is borne primarily by low- and middle-income countries, in particular, in sub-Saharan Africa, where the age-standardized annual incidence is 35 per 100,000 women compared with seven per 100,000 women in North America.2 Cervical cancer is the leading cause of cancer-related death in sub-Saharan Africa.3 The high prevalence and mortality from cervical cancer among African women is multifactorial, as a result of, in part, lack of funding, infrastructure, and access to clinicians. Even in countries with national screening policies, rates of cervical cancer range from 2% to 20% in urban areas and 0.4% to 14% in rural areas.4,5

Women in South Africa are uniquely at risk. This is because of the synergistic effects of a nation that is heavily burdened with HIV6,7 and poor access to adequate diagnostic screening for precancerous lesions.8-10 Women living with HIV (WLWH) have been shown to be at increased susceptibility for the development of precancerous lesions,11-13 including both high-grade squamous intraepithelial lesions (HSILs) and cervical intraepithelial neoplasia (CIN),14-16 and cervical cancer.13,17-20 Unfortunately, most do not receive adequate screening.21-24 despite recommendations made in 2014 that promote annual screening among WLWH.25

Access to antiretroviral therapy (ART) has improved significantly in South Africa since 2005,26 which has resulted in increased life expectancy27 and reduced morbidity.28,29 Yet, linkage studies of HIV and cancer registries have indicated a two- to 22-fold increase in cervical cancer in WLWH compared with HIV-negative women.30-36 These data show that the high
mortality associated with delayed diagnoses of advanced cervical cancer may undermine the benefits of ART in this region. As the government expands care for WLWH, it will be critical to understand the public health burden of cervical dysplasia in this population as well as the feasibility of effective and timely cervical screening for this high-risk population. We undertook this study during a 5-year period to assess the prevalence of screening, cervical dysplasia, and histologic diagnoses from colposcopy and large loop excision of the transformation zone (LLETZ) in a region of South Africa with a high prevalence of HIV.

MATERIALS AND METHODS

Study Design

We performed a retrospective cohort study to determine the prevalence of cervical dysplasia and malignancy among WLWH who attended an urban ART clinic in KwaZulu-Natal, South Africa, during a 5-year period from 2004 to 2009. A random sample of eligible women enrolled in HIV-care was generated from each study year and was stratified by year of ART initiation.

Setting

The Sinikithemba HIV clinic was located at McCord Hospital in Durban, South Africa, and received funding from the President’s Emergency Plan for AIDS Relief from 2004 until it closed in 2012 as a result of shifts in funding. The Sinikithemba cervical screening policy was based on international guidelines. Specifically, the hospital policy was to offer a Papanicolau test (Pap) within the first 3 months of initiating ART, a second smear within the first year, and annual smears thereafter. In addition to receiving annual Pap smears, women were referred for colposcopy and/or LLETZ if they were found to have a single Pap test with HSIL or two consecutive Pap tests with abnormal cytology, which could have either been two low-grade squamous intraepithelial lesions (LSILs) or one LSIL and one lesion that showed atypical squamous cells of undetermined significance (ASCUS).

Participants

Eligibility criteria included WLWH age > 18 years and who attended the clinic for > 3 months. Women with a hysterectomy before enrollment were excluded. Of 2,891 eligible women, 462 were randomly sampled for inclusion and were stratified by year of ART enrollment at the clinic (n = 77 per annum).

Data Collection and Analysis

Data were abstracted from electronic records to a paper form and included date of birth, CD4+ counts, viral load (VL), and results from initial Papanicolau test, colposcopy, and LLETZ. We also tracked time to colposcopy among women with abnormal Pap smears. Women who presented for colposcopy were presumed to have been referred even if this was not documented in the medical record. Laboratory results that were not recorded in the chart or were noted to be lost or damaged were considered not evaluable for this study.

As a measure of quality control and to determine the reliability of the abstraction instrument, 5% of charts were randomly selected and checked for data accuracy by a second data abstractor (J.G.). Data were entered into an EpilInfo database.

Statistical Analysis

Descriptive statistics (medians and proportions) were used to characterize the variables. The prevalence of abnormality with the initial Pap test was calculated along with the cumulative prevalence of abnormality over the course of the observation period. The incidence of Papanicolau test abnormality was estimated in women with normal initial Pap tests and available subsequent cytology results. For both analyses, Pap smears with ASCUS, LSIL, and HSIL were considered abnormal, and descriptive statistics were also generated for colposcopy outcomes. Cytology and histology results were dichotomized at clinically relevant cutoffs: for cytology—ASCUS, LSIL, or HSIL; and for histology—CIN 1, -2, and -3. Differences in median age, CD4+ count, and VL between women who had

| Characteristic          | All Women (N = 462) | Women With ≥ 1 Pap (n = 432) | Never Pap (n = 30) | P     |
|------------------------|---------------------|------------------------------|-------------------|-------|
| Age, years             | 33.0 (27.9-38.8)    | 33.0 (28.0-38.6)             | 32.2 (27.3-40.5)  | .84   |
| CD4, cells/µL          | 115 (58-174)        | 117.5 (55-177)              | 100.5 (72-131)    | .11   |
| Viral load, copies/mL  | 49 (24-66)          | 49 (24-61)                  | 49 (24-670)       | .28   |

NOTE. Data are given as median (interquartile range).
Abbreviation: Pap, Papanicolau test.
at least one Pap versus those who never had a Pap were determined using an exact Wilcoxon method. Analyses were performed using SAS (SAS/STAT User’s Guide, Version 9.3; SAS Institute, Cary NC).

Ethical approval for this study was obtained from the University of Toronto Ethics Research Committee and from the McCord Hospital Research Ethics Committee.

RESULTS

In our cohort of 462 women who were enrolled in ART care, the median age was 33.0 years (interquartile range [IQR], 27.9 to 38.8). Women had a median baseline CD4+ count of 115 cells/µL (IQR, 58 to 174 cells/µL) and median baseline VL of 49 (IQR, 24 to 66; Table 1). During the study period, 432 women (93.5%) had at least one evaluable Papanicolaou test, and, of those, 330 (76.4%) had two or more Pap smears (median, 3; IQR, 2 to 4). There were no significant differences between women who received at least one Pap test and those who never had a Pap with respect to age (33.0 years \(v\) 32.2 years; \(P = .84\), baseline CD4+ \(v\) 118 cells/µL; \(P = .11\), or VL (49 \(v\) 49; \(P = .84\)), baseline CD4+ (118 \(v\) 100 cells/µL; \(P = .11\)), or VL (49 \(v\) 49; \(P = .84\)).

In this study, 237 women (54.9%) had an abnormal Pap test at baseline, when they initiated ART. Of 237 women with abnormal Pap smears, 62 (26.2%) had ASCUS and these women were followed with sequential Pap smears. Of 175 remaining women, 125 (28.9%) had LSIL and 50 (11.6%) had HSIL, which warranted immediate referral for colposcopy. Figure 1 shows the progression of women, both those who qualified and those who did not, with Pap smears through colposcopy and subsequent histologic results. Of 181 women who qualified for colposcopy during the study period, 72.4% \(n = 131\) were referred. Of these, 115 (87.8%) had documentation of completed colposcopy within a median of 39 days (IQR, 20 to 95 days).

Referrals yielded 74 (64.3%) of 115 evaluable histologic samples, and of these, 75.6% were found to have CIN. Specifically, 21.6%, 27.0%, and 27.0% had CIN1, CIN2, and CIN3, respectively. In addition, 1.4% were found to have invasive cervical cancer (Fig 1).

DISCUSSION

In a cohort of WLWH who accessed care at an urban clinic in KwaZulu-Natal, South Africa, where Pap test coverage and rates for referral for colposcopy and LLETZ were high, we observed that \(> 75%\) of women with evaluable histologic samples had evidence of cervical dysplasia or malignancy. In addition, we found the crude incidence of invasive cervical cancer to be \(> 200\)-fold higher than incidence rates of cervical cancer in the United States (seven per 100,000).49

Prior studies in South Africa have shown similarly high rates of premalignant lesions on cytology from Pap smears, with prevalence of HSIL = 33% in WLWH.21 These findings demonstrate the significant public health burden of cervical dysplasia in this population. Given that invasive cervical cancer is preceded by gradual progression of premalignant CIN,41-44 our findings highlight the importance of cervical screening upon entry into care to optimize the potential for early interventions and cure. This is essential among WLWH, given the higher prevalence of CIN11,13 and the worse treatment outcomes among this population compared with HIV-negative women.15-47

WLWH in South Africa now have improved access to ART, and, provided they start treatment before their CD4+ count drops < 200 cells/µL, they are expected to have a near normal life expectancy.48 Yet the benefits of ART may be undermined by the risk of cervical cancer acquisition.49 Prior research has shown that ART is associated with increased regression of squamous intraepithelial lesions among WLWH.52
Despite this, the majority of cervical cancers among WLWH, even among individuals who are on treatment, do not regress to normal.51

As South Africa continues to expand care for those living with HIV,38 national outreach programs should be revised to reflect the higher risk of cervical cancer among WLWH. It is also critical to reach women who may not be accessing care.52 Improved screening services will require more resources and infrastructure throughout sub-Saharan Africa, coupled with integrated, community-based health education to emphasize the need for regular screening. This will ultimately enable clinicians to provide timely diagnoses and referrals for cervical abnormalities.

This study is limited by the fact that these data were collected retrospectively from a single site and, therefore, may be limited in generalizability. Furthermore, all participants in this study were already receiving ART, thereby precluding our ability to determine the effect of treatment on screening. Despite these limitations, these data provide histologic evidence of the burden of cervical disease in this high-risk population that is rarely seen in the literature, given the paucity of centers providing colposcopy and LLETZ in sub-Saharan Africa.

South African policymakers must ensure coordination and resourcing of sexual and reproductive health programs as well as their integration with HIV treatment programs. The Department of Health needs to develop a national cancer control program, with an investment in capacity building to ensure accurate evaluation of the burden of disease,33 including both cancer detection and treatment, to support women with HIV so that they may live long and healthy lives.

DOI: 10.1200/JGO.2015.002469
Published online on ascopubs.org/journal/jgo on May 4, 2016.

AUTHOR CONTRIBUTIONS
Conception and design: Ingrid T. Katz, Lisa M. Butler, Tamaryn L. Crankshaw, Karen Bramhill, Janet Giddy, Sean Mould
Provision of study materials or patients: Tamaryn L. Crankshaw, Janet Giddy, Sean Mould
Collection and assembly of data: Lisa M. Butler, Tamaryn L. Crankshaw, Karen Bramhill, Dominick A. Leone, Janet Giddy, Sean Mould
Data analysis and interpretation: Ingrid T. Katz, Lisa M. Butler, Tamaryn L. Crankshaw, Alexi A. Wright, Dominick A. Leone, Janet Giddy, Sean Mould
Manuscript writing: All authors
Final approval of manuscript: All authors

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Ingrid T. Katz
No relationship to disclose
Lisa M. Butler
No relationship to disclose
Tamaryn L. Crankshaw
No relationship to disclose
Alexi A. Wright
No relationship to disclose
Karen Bramhill
No relationship to disclose
Dominick A. Leone
No relationship to disclose
Janet Giddy
No relationship to disclose
Sean Mould
No relationship to disclose

Affiliations
Ingrid T. Katz and Dominick A. Leone, Brigham and Women’s Hospital; Ingrid T. Katz, Lisa M. Butler, and Alexi A. Wright, Harvard Medical School; Ingrid T. Katz, Massachusetts General Hospital Center for Global Health; Lisa M. Butler, Boston Children’s Hospital; Alexi A. Wright, Dana-Farber Cancer Institute; Dominick A. Leone, Boston University, Boston, MA; Tamaryn L. Crankshaw, University of KwaZulu-Natal, Durban; Janet Giddy, Western Cape Province Department of Health, Cape Town; Sean Mould, R.K. Khan Hospital, Chatsworth, South Africa; and Karen Bramhill, Canadian Red Cross, Ontario, Canada.

REFERENCES
1. Ferlay J, Soerjomataram I, Ervik M, et al: GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France, International Agency for Research on Cancer. http://globocan.iarc.fr
2. Fokom-Domgue J, Combescure C, Fokom-Defo V, et al: Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: Systematic review and meta-analysis of diagnostic test accuracy studies. BMJ 351:h3084, 2015
3. Parkin DM, Bray F, Ferlay J, et al: Cancer in Africa 2012. Cancer Epidemiol Biomarkers Prev 23:953-966, 2014
4. Louie KS, de Sanjose S, Mayaud P: Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: A comprehensive review. Trop Med Int Health 14:1287-1302, 2009
5. Brower V: AIDS-related cancers increase in Africa. J Natl Cancer Inst 103:918-919, 2011
6. Central Intelligence Agency: The world factbook. https://www.cia.gov/library/publications/resources/the-world-factbook/
7. Joint United Nations Programme on HIV/AIDS: Global report: UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf
8. Francis SA, Battle-Fisher M, Liverpool J, et al: A qualitative analysis of South African women’s knowledge, attitudes, and beliefs about HPV and cervical cancer prevention, vaccine awareness and acceptance, and maternal-child communication about sexual health. Vaccine 29:8760-8765, 2011
9. Jemal A, Center MM, DeSantis C, et al: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907, 2010
10. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150, 2006
11. Conti M, Agarossi A, Parazzini F, et al: HPV, HIV infection, and risk of cervical intraepithelial neoplasia in former intravenous drug abusers. Gynecol Oncol 49:344-348, 1993
12. Wang C, Wright TC, Denny L, et al: Rapid rise in detection of human papillomavirus (HPV) infection soon after incident HIV infection among South African women. J Infect Dis 203:479-486, 2011
13. Wright TC Jr, Ellerbrock TV, Chiasson MA, et al: Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: Prevalence, risk factors, and validity of Papanicolaou smears. New York Cervical Disease Study. Obstet Gynecol 84:591-597, 1994
14. KwaZulu-Natal Department of Health: Sexual, reproductive and youth health: Student training modules: Professional nurses. 2004
15. South Africa Department of Health: National guidelines for cervical cancer screening programme. http://screening.iarc.fr/doc/SACervical-cancer.pdf
16. Sibiya N, Grainger L: Registered nurses’ perceptions of the cervical screening programme in primary health care clinics in the KwaZulu-Natal province of South Africa. Afr J Nurs Midwifery 12:15-26, 2010
17. Chin KM, Sidhu JS, Janssen RS, et al: Invasive cervical cancer in human immunodeficiency virus-infected and uninfected hospital patients. Obstet Gynecol 92:83-87, 1998
18. Conley LJ, Ellerbrock TV, Bush TJ, et al: HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: A prospective cohort study. Lancet 359:108-113, 2002
19. Franco EL, Duarte-Franco E, Ferency A: Cervical cancer: Epidemiology, prevention and the role of human papillomavirus infection. CMAJ 164:1017-1025, 2001
20. Sun XW, Kuhn L, Ellerbrock TV, et al: Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 337:1343-1349, 1997
21. Firthaber C, Mayisela N, Mao L, et al: Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. PLoS One 8:e53494, 2013
22. Firthaber C, Van Le H, Pettifor A, et al: Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control 21:433-443, 2010
23. Hoque M, Hoque E, Kader SB: Evaluation of cervical cancer screening program at a rural community of South Africa. East Afr J Public Health 5:111-116, 2008
24. Moodley M, Moodley J, Kleinschmidt I: Invasive cervical cancer and human immunodeficiency virus (HIV) infection: A South African perspective. Int J Gynecol Cancer 11:194-197, 2001
25. Republic of South Africa: National Consolidated Guidelines for the Prevention of Mother-to-Child Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescents and Adults. Pretoria, South Africa, Department of Health, 2014
26. Joint United Nations Programme on HIV/AIDS: The gap report. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf
27. Bor J, Herbst AJ, Newell ML, et al: Increases in adult life expectancy in rural South Africa: Valuing the scale-up of HIV treatment. Science 339:961-965, 2013
28. Kahn JG, Marseille EA: Capsule commentary on Long and Stavert, portfolios of biomedical HIV interventions in South Africa: A cost-effectiveness analysis. J Gen Intern Med 28:1350, 2013
29. Ngzali MD, West SJ, Dave JA, et al: Quality of life in individuals living with HIV/AIDS attending a public sector antiretroviral service in Cape Town, South Africa. BMC Public Health 14:676, 2014
30. Adler DH: The impact of HAART on HPV-related cervical disease. Curr HIV Res 8:493-497, 2010
31. Dal Maso L, Franceschi S, Lise M, et al: Self-reported history of Pap-smear in HIV-positive women in northern Italy: A cross-sectional study. BMC Cancer 10:310, 2010
32. De Vuyst H, Lillo F, Broutet N, et al: HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 17:545-554, 2008
33. Denny L: Control of cancer of the cervix in low- and middle-income countries. Ann Surg Oncol 22:728-733, 2015
34. Grulich AE, van Leeuwen MT, Falster MO, et al: Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 370:59-67, 2007
35. Mbulaiteye SM, Katabira ET, Wabinga H, et al: Spectrum of cancers among HIV-infected persons in Africa: The Uganda AIDS-Cancer Registry Match Study. Int J Cancer 118:985-990, 2006
36. Six C, Heard I, Bergeron C, et al: Comparative prevalence, incidence and short-term prognosis of cervical squamous intraepithelial lesions amongst HIV-positive and HIV-negative women. AIDS 12:1047-1056, 1998
37. Cloete C, Regan S, Giddy J, et al: The linkage outcomes of a large-scale, rapid transfer of HIV-infected patients from hospital-based to community-based clinics in South Africa. Open Forum Infect Dis 1:ofu058, 2014
38. Katz IT, Bassett IV, Wright AA: PEPFAR in transition–Implications for HIV care in South Africa. N Engl J Med 369:1385-1387, 2013
39. Katz IT, Bogart LM, Cloete C, et al: Understanding HIV-infected patients’ experiences with PEPFAR-associated transitions at a Centre of Excellence in KwaZulu Natal, South Africa: A qualitative study. AIDS Care 27:1298-1303, 2015
40. National Cancer Institute: SEER cancer statistics review (CSR), 1975-2011. http://seer.cancer.gov/csr/1975_2012/
41. Adam Y, McIntyre JA, De Bruyn G: Incidence of cytological abnormalities within 24 months of a normal cervical smear in Soweto, South Africa. S Afr Med J 103:34-39, 2012
42. Anderson MC, Brown CL, Buckley CH, et al: Current views on cervical intraepithelial neoplasia. J Clin Pathol 44:969-978, 1991
43. Cantor SB, Atkinson EN, Cardenas-Turanzas M, et al: Natural history of cervical intraepithelial neoplasia: A meta-analysis. Acta Cytol 49:405-415, 2005
44. Ostör AG: Natural history of cervical intraepithelial neoplasia: A critical review. Int J Gynecol Pathol 12:186-192, 1993
45. Barnbury J, Mullings A, Fletcher H, et al: Cervical intraepithelial neoplasia in a cohort of HIV-positive women at the University Hospital of the West Indies: Management and outcome. West Indian Med J 62:313-317, 2013
46. Mungo C, Cohen CR, Maloba M, et al: Prevalence, characteristics, and outcomes of HIV-positive women diagnosed with invasive cancer of the cervix in Kenya. Int J Gynaecol Obstet 123:231-235, 2013
47. Russomano F, Paz BR, Camargo MJ, et al: Recurrence of cervical intraepithelial neoplasia in human immunodeficiency virus-infected women treated by means of electrosurgical excision of the transformation zone (LLETZ) in Rio de Janeiro, Brazil. Sao Paulo Med J 131:405-410, 2013
48. Johnson LF, Mossong J, Dorrrington RE, et al: Life expectancies of South African adults starting antiretroviral treatment: Collaborative analysis of cohort studies. PLoS Med 10:e1001418, 2013
49. Moodley JR, Constant D, Hoffman M, et al: Human papillomavirus prevalence, viral load and pre-cancerous lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: A cross-sectional study. BMC Cancer 9:275, 2009
50. Omar T, Schwartz S, Hanrahan C, et al: Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: A prospective cohort. AIDS 25:87-94, 2011
51. Ahdieh-Grant L, Li R, Levine AM, et al: Highly active antiretroviral therapy and cervical squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Natl Cancer Inst 96:1070-1076, 2004
52. Katz IT, Dietrich J, Tshabalala G, et al: Understanding treatment refusal among adults presenting for HIV-testing in Soweto, South Africa: A qualitative study. AIDS Behav 19:704-714, 2015